Brookline Capital Management Comments on CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at Brookline Capital Management cut their Q2 2025 earnings per share estimates for CRISPR Therapeutics in a report issued on Tuesday, May 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($1.23) per share for the quarter, down from their prior estimate of ($0.86). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.31) EPS, FY2026 earnings at $2.55 EPS, FY2027 earnings at $4.70 EPS, FY2028 earnings at $8.73 EPS and FY2029 earnings at $43.19 EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. The firm's revenue was up 71.6% on a year-over-year basis. During the same period last year, the business posted ($1.43) earnings per share.

Other research analysts have also issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Needham & Company LLC dropped their target price on CRISPR Therapeutics from $84.00 to $81.00 and set a "buy" rating on the stock in a report on Wednesday. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. TD Cowen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective on the stock in a report on Wednesday, February 12th. Finally, Truist Financial upped their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP traded down $0.52 during trading on Friday, reaching $35.62. The company had a trading volume of 1,737,782 shares, compared to its average volume of 1,669,417. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -8.15 and a beta of 1.88. The stock's fifty day moving average price is $38.15 and its 200 day moving average price is $42.71. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $67.88.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock worth $353,180,000 after acquiring an additional 1,474,439 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after buying an additional 1,074,238 shares during the period. Capital International Investors raised its holdings in shares of CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after buying an additional 816,789 shares during the period. Baker BROS. Advisors LP grew its stake in CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock valued at $51,483,000 after purchasing an additional 464,936 shares in the last quarter. Finally, Norges Bank acquired a new stake in CRISPR Therapeutics during the 4th quarter valued at approximately $17,458,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Julianne Bruno sold 1,198 shares of the company's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 2,850 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares in the company, valued at $3,288,822.60. This represents a 3.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock worth $1,608,243 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.